Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.34 |
| ▸ | OXTR | P30559 | 2/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.34 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22858733 | 1.00 | NPC1 (0.38) | NPC1GAARAB9AKMT2ANSD2 | |
| SCHEMBL22858814 | 0.86 | NSD2 (0.44) | NPC1GAARAB9AKMT2ANSD2 | |
| SCHEMBL22858813 | 0.86 | NSD2 (0.44) | NPC1GAARAB9AKMT2ANSD2 | |
| SCHEMBL22922417 | 0.86 | NSD2 (0.44) | NPC1GAARAB9AKMT2ANSD2 | |
| SCHEMBL22858905 | 0.79 | NPC1 (0.41) | NPC1GAARAB9AKMT2ANSD2 | |
| SCHEMBL22858909 | 0.79 | NPC1 (0.41) | NPC1GAARAB9AKMT2ANSD2 | |
| SCHEMBL22858976 | 0.79 | NSD2 (0.35) | NPC1GAARAB9AKMT2ANSD2 | |
| SCHEMBL2802162 | 0.77 | HIF1A (0.36) | HIF1AROCK1LIPG | |
| SCHEMBL22858943 | 0.77 | HIF1A (0.36) | HIF1AROCK1LIPG | |
| SCHEMBL2799366 | 0.76 | LIPG (0.38) | HIF1AROCK1LIPGCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459958-B2 | Tricyclic compounds as HPK1 inhibitor and the use thereof | BEONE MEDICINES I GMBH (CH) | 2025-11-04 | — | — | US | disclosed |
| US-12454534-B2 | Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof | BEONE MEDICINES I GMBH (CH) | 2025-10-28 | — | — | US | disclosed |
| CN-115073474-A | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115028639-A | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-20220267354-A1 | TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-08-25 | — | — | US | disclosed |
| US-20220267333-A1 | PYRROLO[2,3-b]PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-08-25 | — | — | US | disclosed |
| EP-3994136-A1 | PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BeiGene, Ltd. (KY) | 2022-05-11 | — | — | EP | disclosed |
| WO-2021013083-A1 | TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021000925-A1 | PYRROLO [2, 3-b] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267354-A1 | TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | ULK1, SBK1, PHKG1 | NPC1 210/4885GAA 646/4885RAB9A 1990/4885 |
| US-20220267333-A1 | PYRROLO[2,3-b]PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | PDXK, STK25, STK35 | NPC1 1058/4885GAA 1683/4885RAB9A 1820/4885 |
| US-12454534-B2 | Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof | PDXK, STK25, STK35 | NPC1 1058/4885GAA 1683/4885RAB9A 1820/4885 |
| US-12459958-B2 | Tricyclic compounds as HPK1 inhibitor and the use thereof | ULK1, SBK1, PHKG1 | NPC1 210/4885GAA 646/4885RAB9A 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.